ReviewFrontiers in pharmacology2020
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021Pooled it
- Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.International immunopharmacology · 2020Trial
- Selected Cannabinoids, Cannabimimetic Agents andPharmaceuticals (Basel, Switzerland) · 2026Review
- Highly sensitive and selective electrochemical determination of curcumin using a polyaniline-based molecularly imprinted polymer.RSC advances · 2026Article
- Real-World Evaluation Study of Azvudine for the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Review
- An update in the applications of exosomes in cancer theranostics: from research to clinical trials.Journal of cancer research and clinical oncology · 2023Review
- Propolis: An update on its chemistry and pharmacological applications.Chinese medicine · 2022Review
- A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives.Journal, genetic engineering & biotechnology · 2022Review
- COVID-19 in children: acute endotheliopathy, but forgotten prostacyclin replacement?Cardiology in the young · 2022Article
- The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Article
- Novel Coronavirus (SARS-CoV-2) in Water and Environment-A Scoping Review.Life (Basel, Switzerland) · 2022Article
- Inhibition of the SARS-CoV-2 3CLFood chemistry · 2022Article
- Anticipated pharmacological role of Aviptadil on COVID-19.Environmental science and pollution research international · 2022Review
- Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.Frontiers in pharmacology · 2022Article
- Impact of COVID-19 acute respiratory disease on the risk factors attributed to cancer patients.Toxicology reports · 2022Review
- mTOR kinase is a therapeutic target for respiratory syncytial virus and coronaviruses.Scientific reports · 2021Article
- Haematological malignancies implications during the times of the COVID-19 pandemic.Oncology letters · 2021Review
- Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review.Annals of medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2. With the rapid evolution of the pandemic, even the off-label use of existing drugs has been restricted by limited availability. Several old antivirals, antimalarial, and biological drugs are being reconsidered as possible therapies. The effectiveness of the controversial treatment options for COVID-19 such as nonsteroidal antiinflammatory drugs, angiotensin 2 conversion enzyme inhibitors and selective angiotensin receptor blockers was also discussed. A systemic search in the PubMed, Science Direct, LitCovid, Chinese Clinical Trial Registry, and ClinicalTrials.gov data bases was conducted using the keywords "coronavirus drug therapy," passive immunotherapy for COVID-19', "convalescent plasma therapy," (CPT) "drugs for COVID-19 treatment," "SARS-CoV-2," "COVID-19," "2019-nCoV," "coronavirus immunology," "microbiology," "virology," and individual drug names. Systematic reviews, case presentations and very recent clinical guidelines were included. This narrative review summarizes the available information on possible therapies for COVID-19, providing recent data to health professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.